Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time

BRANFORD, Conn.–(BUSINESS WIRE)–Apr. 30, 2024–
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced upgrades to its Platinum® Analysis Software to reduce processing time and increase output and precision of Next-Generation Protein Sequencing™ (NGPS) data from the Platinum® instrument.

“A core component of our Platinum Analysis Software is a database of predicted kinetic signatures that today, contains nearly two million parameters and is generated by our proprietary kinetic model,” said John Vieceli, Senior Vice President of Product Development at Quantum-Si. “Leveraging artificial intelligence and generated sequencing data, we are able to continuously train our model and improve the accuracy of the database, resulting in higher data output and precision.”

Innovations in this release of the Platinum Analysis Software will provide customers with an average of:

  • 55% increase in the number of peptide alignments of protein samples

  • 9% increase in the precision of identifying unknown proteins present in a given sample

  • 70% reduction in primary analysis time from 85 minutes to 25 minutes

“Innovations to our Platinum Analysis Software represent a significant opportunity to unlock even deeper insights from our Next-Generation Protein Sequencing technology further building upon the improvements we continue to deliver to the sequencing chemistry,” said Jeff Hawkins, President and CEO of Quantum-Si. “The Platinum Analysis Software enhancements we are launching today represent another significant leap forward in our commitment to continuously provide customers with innovations that deliver tangible value to their proteomics research.”

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantumsi.supremeclients.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact

Jeff Keyes, Chief Financial Officer

[email protected]

Media Contact

Katherine Atkinson, SVP, Commercial Marketing

[email protected]

Source: Quantum-Si Incorporated

RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.